Combinations of different therapeutic strategies, including
chemotherapy
(CT), chemodynamic therapy (CDT), and photothermal therapy (PTT),
are needed to effectively address evolving drug resistance and the
adverse effects of traditional cancer treatment. Herein, a camouflage
composite nanoformulation (TCBG@PR), an antitumor agent (tubercidin,
Tub) loaded into Cu-doped bioactive glasses (CBGs) and subsequently
camouflaged by polydopamine (PDA), and red blood cell membranes (RBCm),
was successfully constructed for targeted and synergetic antitumor
therapies by combining CT of Tub, CDT of doped copper ions, and PTT
of PDA. In addition, the TCBG@PRs composite nanoformulation was camouflaged
with a red blood cell membrane (RBCm) to improve biocompatibility,
longer blood retention times, and excellent cellular uptake properties.
It integrated with long circulation and multimodal synergistic treatment
(CT, CDT, and PTT) with the benefit of RBCms to avoid immune clearance
for efficient targeted delivery to tumor locations, producing an “all-in-one”
nanoplatform. In vivo results showed that the TCBG@PRs composite nanoformulation
prolonged blood circulation and improved tumor accumulation. The combination
of CT, CDT, and PTT therapies enhanced the antitumor therapeutic activity,
and light-triggered drug release reduced systematic toxicity and increased
synergistic antitumor effects
